Physician profile
Keith Laskin
NPI 1821064783
$3,404.08
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $437 · 2021: $990 · 2022: $711 · 2023: $64.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.61 | 2019-2023 | |
| Pfizer INC. | $406.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $362.14 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.50 | 2019-2022 | |
| Janssen Biotech, INC. | $270.78 | 2019-2022 | |
| Celgene Corporation | $215.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $108.35 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $108.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.76 | 2019-2022 | |
| Shire North American Group INC | $55.89 | 2019 | |
| Nestle Healthcare Nutrition INC. | $55.03 | 2021-2023 | |
| Redhill Biopharma INC. | $33.32 | 2020-2022 | |
| Dova Pharmaceuticals | $29.71 | 2019 | |
| Echosens North America, INC. | $23.55 | 2019 | |
| Ucb, INC. | $23.13 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $22.01 | 2021 | |
| Alfasigma USA, INC. | $21.89 | 2020 | |
| Axonics, INC. | $15.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.55 | 2021 | |
| Qol Medical, LLC | $15.14 | 2021 | |
| Medtronic, INC. | $13.53 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Laskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.